Center coordinating development of new treatments for glioblastoma
Administrative Core
Combines new drugs that block tumor DNA repair with standard chemotherapy and radiation to improve treatment for people with glioblastoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11189636 on NIH RePORTER |
What this research studies
From a patient's perspective, this center brings together lab and clinical teams to find better ways to make standard glioblastoma treatments work stronger by adding drugs that target DNA damage repair in tumors. Researchers will test combinations in lab models made from patient tumors and study how drugs reach and affect the brain using pharmacokinetic and pharmacodynamic tests. Promising combinations will guide small pilot clinical trials where patients can receive these drug combinations alongside usual care. An administrative core at Mayo Clinic will coordinate the work and connect patients and clinicians across the glioma research network.
Who could benefit from this research
Good fit: Adults with glioblastoma who are eligible for early-phase clinical trials of DNA damage response inhibitor combinations with standard genotoxic therapies would be ideal candidates.
Not a fit: People without glioblastoma or those unable to tolerate chemotherapy, radiation, or experimental drugs are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this work could make chemotherapy and radiation more effective against glioblastoma and lead to new treatment options.
How similar studies have performed: Similar DNA-repair inhibitor combinations have helped some other cancers but remain experimental and face special challenges in glioblastoma, so this approach is partly novel for brain tumors.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Sarkaria, Jann N. — Mayo Clinic Rochester
- Study coordinator: Sarkaria, Jann N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.